The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer

Clinical Cancer Research

Volumn 12, Issue 4, 2006, Pages 1157-1167

  Olivier, Magali ^a   Langerød, Anita ^b   Carrieri, Patrizia ^c   Bergh, Jonas ^d   Klaar, Sigrid ^d   Eyfjord, Jorunn ^e   Theillet, Charles ^f   Rodriguez, Carmen ^f   Lidereau, Rosette ^g   Bièche, Ivan ^g   Varley, Jennifer ^h   Bignon, Yves ⁱ   Uhrhammer, Nancy ⁱ   Winqvist, Robert ^j   Jukkola Vuorinen, Arja ^j   Niederacher, Dieter ^k   Kato, Shunsuke ^l   Ishioka, Chikashi ^l   Hainaut, Pierre ^a   Børresen Dale, Anne Lise ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY OF OSLO   (Norway)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF ICELAND   (Iceland)

^f CENTRE VAL D AURELLE   (France)

^g CENTRE RENÉ HUGUENIN   (France)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ CENTRE JEAN PERRIN   (France)

^j OULU UNIVERSITY HOSPITAL   (Finland)

^k UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^l TOHOKU UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GENOMIC DNA; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SIZE; CODON; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SOMATIC MUTATION; TP53 GENE; TUMOR SUPPRESSOR GENE;

EID: 33644772215     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1029     Document Type: Article

References (49)

1. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
2. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
3. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
4. Borresen AL, Andersen TI, Eyfjord JE, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14:71-5.
5. Kihara C, Seki T, Furukawa Y, et al. Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients. Jpn J Cancer Res 2000;91:190-8.
6. Temam S, Flahault A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000;18:385-94.
7. Skaug V, Ryberg D, Kure EH, et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000;6:1031-7.
8. Resnick MA, Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A 2003;100:9934-9.
9. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 2003;100:8424-9.
10. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999;80:1968-73.
11. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993;68:540-8.
12. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 1997;181:140-5.
13. Cuny M, Kramar A, Courjal F, et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 2000;60:1077-83.
14. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
15. Thorlacius S, Borresen AL, Eyfjord JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 1993;53:1637-41.
16. Gretarsdottir S, Tryggvadottir L, Jonasson JG, et al. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 1996;74:555-61.
17. Sorlie T, Johnsen H, Vu P, Lind GE, Lothe R, Borresen-Dale AL. Mutation Screening of the TP53 gene by temporal temperature gradient gel electrophoresis. Methods Mol Biol 2004;291:207-16.
18. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
19. Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Semin Cancer Biol 2001;11:353-60.
20. Martin AC, Facchiano AM, Cuff AL, et al. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 2002;19:149-64.
21. Jong YJ, Li LH, Tsou MH, et al. Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. Cancer Genet Cytogenet 2004;148:55-65.
22. Sigurdsson S, Bodvarsdottir SK, Anamthawat-Jonsson K, et al. p53 abnormality and chromosomal instability in the same breast tumor cells. Cancer Genet Cytogenet 2000;121:150-5.
23. Eyfjord JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir HM, Anamthawat-Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 1995;55:646-51.
24. Lindahl T, Landberg G, Ahlgren J, et al. Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 2004;25:375-80.
25. Chappuis PO, Estreicher A, Dieterich B, et al. Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999;84:587-93.
26. Kucera E, Speiser P, Gnant M, et al. Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group. Eur J Cancer 1999;35:398-405.
27. De Cremoux P, Salomon AV, Liva S, et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst 1999;91:641-3.
28. Eisinger F, Jacquemier J, Charpin C, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998;58:1588-92.
29. Rebbeck TR. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer 1999;86:2493-501.
30. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 2000;6:443-51.
31. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000;39:327-33.
32. Pichon MF, Pallud C, Brunet M, Milgrom E. Relationship of presence of progesterone receptors to prognosis in early breast cancer. Cancer Res 1980;40:3357-60.
33. Bernoux A, De Cremoux P, Laine-Bidron C, Martin EC, Asselain B, Magdelenat H. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat 1998;49:219-25.
34. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9.
35. Berns EM, Foekens JA, Vossen R, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-62
36. Erster S, Moll UM. Stress-induced p53 runs a transcription-independent death program. Biochem Biophys Res Commun 2005;331:843-50.
37. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005;331:834-42.
38. Aas T, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-4.
39. Geisler S, Lonning PE, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
40. Geisler S, Borresen-Dale AL, Johnsen H, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003;9:5582-8.
41. Takahashi M, Tonoki H, Tada M, et al. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 2000;89:92-9.
42. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003;63:6643-50.
43. Jerry DJ, Kittrell FS, Kuperwasser C, et al. A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development. Oncogene 2000;19:1052-8.
44. Glidden DV, Vittinghoff E. Modelling clustered survival data from multicentre clinical trials. Stat Med 2004;23:369-88.
45. Bull SB, Ozcelik H, Pinnaduwage D, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 2004;22:86-96.
46. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
47. Suspitsin EN, Buslov KG, Grigoriev MY, et al. Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 2003;103:431-3.
48. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-37.
49. Tonisson N, Zernant J, Kurg A, et al. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc Natl Acad Sci U S A 2002;99:5503-8.